NeoGenomics (MEX:NEO) Marketable Securities: MXN0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NEO NeoGenomics Inc MEX:NEO
62 GF Score
Price MXN176.40
GF Value MXN479.12
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Marketable Securities?

NeoGenomics MEX:NEO 62 Marketable Securities is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:NEO with a GF Score™ of 62/100 and a GF Value™ of MXN479.12 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. NeoGenomics's Marketable Securities for the quarter that ended in Mar. 2026 was MXN0 Mil.

NeoGenomics's annual Marketable Securities declined from Dec. 2023 (MXN1,234 Mil) to Dec. 2024 (MXN414 Mil) and declined from Dec. 2024 (MXN414 Mil) to Dec. 2025 (MXN0 Mil).

NeoGenomics  (MEX:NEO) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

NeoGenomics Marketable Securities Related Terms

NeoGenomics Marketable Securities Historical Data

* Premium members only.

The historical data trend for NeoGenomics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Marketable Securities Chart

NeoGenomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,073.32 3,408.08 1,234.28 413.61 0.00

NeoGenomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 243.17 168.75 0.00 0.00 0.00
MEX:NEO
62GF Score
NeoGenomics Inc MEX:NEO
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeoGenomics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of MXN0 Mil mean?
NeoGenomics (MEX:NEO) has a Marketable Securities of MXN0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on NeoGenomics and its competitors.
Is NeoGenomics' Marketable Securities too high?
NeoGenomics' current Marketable Securities is MXN0 Mil. Overall, NeoGenomics has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Marketable Securities compare to WGS and CDNA?
NeoGenomics' Marketable Securities of MXN0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Diagnostics & Research company?
A good Marketable Securities depends on the Medical Diagnostics & Research industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on NeoGenomics and its competitors. NeoGenomics's current Marketable Securities is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
Based on GuruFocus' analysis, NeoGenomics (MEX:NEO) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN479.12, compared to a current price of MXN176.40 — trading 63.2% below its estimated fair value. The current Marketable Securities is MXN0 Mil. NeoGenomics' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For NeoGenomics (MEX:NEO), the current Marketable Securities is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeoGenomics (MEX:NEO) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of MXN176.40 is trading 63.2% below its estimated GF Value™ of MXN479.12. GuruFocus considers NeoGenomics to be Significantly Undervalued.

Key valuation signals for MEX:NEO:

  • Marketable Securities: MXN0 Mil
  • GF Value™: MXN479.12 vs. price of MXN176.40 (63.2% below fair value)
  • GF Score™: 62/100 with 6 warning signs

No single metric tells the full story. See the MEX:NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeoGenomics Business Description

Other Exchanges NEO:USANG9:Germany
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
62GF Score

Get the complete analysis for MEX:NEO

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN176.40
Price
MXN479.12
GF Value